Evidence map›Paper›PMID 33465063›Full record

ArticlePLoS medicine2021

Risk of developing active tuberculosis following tuberculosis screening and preventive therapy for Tibetan refugee children and adolescents in India: An impact assessment.

Kunchok Dorjee, Sonam Topgyal, Tenzin Tsewang, Tenzin Tsundue, Tenzin Namdon, Elizabeth Bonomo, Caroline Kensler, Dekyi Lhadon, Tsering Choetso, Tenzin Nangsel and 7 more

Open access · goldAbstract read
In one paragraph

Article in PLoS medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Kunchok DorjeeCenter for TB Research, Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.ORCID 0000-0003-0992-0631
Sonam TopgyalDivision of Tuberculosis, Delek Hospital, Department of Health, Central Tibetan Administration, Dharamsala, India.
Tenzin TsewangDivision of Tuberculosis, Delek Hospital, Department of Health, Central Tibetan Administration, Dharamsala, India.
Tenzin TsundueDivision of Tuberculosis, Delek Hospital, Department of Health, Central Tibetan Administration, Dharamsala, India.ORCID 0000-0002-2687-5839
Tenzin NamdonDivision of Tuberculosis, Delek Hospital, Department of Health, Central Tibetan Administration, Dharamsala, India.
Elizabeth BonomoCenter for TB Research, Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.ORCID 0000-0001-7059-6127
Caroline KenslerCenter for TB Research, Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.
Dekyi LhadonDivision of Tuberculosis, Delek Hospital, Department of Health, Central Tibetan Administration, Dharamsala, India.
Tsering ChoetsoDivision of Tuberculosis, Delek Hospital, Department of Health, Central Tibetan Administration, Dharamsala, India.
Tenzin NangselDivision of Tuberculosis, Delek Hospital, Department of Health, Central Tibetan Administration, Dharamsala, India.
Tsering DolkarDivision of Tuberculosis, Delek Hospital, Department of Health, Central Tibetan Administration, Dharamsala, India.
Thupten TsekyiDivision of Tuberculosis, Delek Hospital, Department of Health, Central Tibetan Administration, Dharamsala, India.
Chungdak DorjeeTibetan Children's Village School, Dharamsala, India.ORCID 0000-0001-8404-1325
Dawa PhunkyiDivision of Tuberculosis, Delek Hospital, Department of Health, Central Tibetan Administration, Dharamsala, India.
Tsetan D SadutshangDivision of Tuberculosis, Delek Hospital, Department of Health, Central Tibetan Administration, Dharamsala, India.
Zorba PasterDepartment of Family Medicine, University of Wisconsin, Madison, Wisconsin, United States of America.
Richard E ChaissonCenter for TB Research, Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.
Tibetan Delek Hospital · INJohns Hopkins University · USTibetan Children’s Village · INUniversity of Wisconsin–Madison · US

Funding

Tuberculosis Transmission and Preventive Therapy in Tibetan Children and Young Adults in IndiaK01AI148583 · NIAID · JOHNS HOPKINS UNIVERSITY · PI DORJEE, KUNCHOK · 2020 to 2024
$734k
NIAID NIH HHS K01 AI148583
6 · The paper itself

Abstract

backgroundTuberculosis (TB) rates among Tibetan refugee children and adolescents attending boarding schools in India are extremely high. We undertook a comprehensive case finding and TB preventive treatment (TPT) program in 7 schools in the Zero TB Kids project. We aimed to measure the TB infection and disease burden and investigate the risk of TB disease in children and adults who did and did not receive TPT in the schools. METHODS AND

findingsA mobile team annually screened children and staff for TB at the 7 boarding schools in Himachal Pradesh, India, using symptom criteria, radiography, molecular diagnostics, and tuberculin skin tests. TB infection (TBI) was treated with short-course regimens of isoniazid and rifampin or rifampin. TB disease was treated according to Tibetan and Indian guidelines. Between April 2017 and December 2019, 6,582 schoolchildren (median age 14 [IQR 11-16] years) and 807 staff (median age 40 [IQR 33-48] years) were enrolled. Fifty-one percent of the students and 58% of the staff were females. Over 13,161 person-years of follow-up in schoolchildren (median follow-up 2.3 years) and 1,800 person-years of follow-up in staff (median follow-up 2.5 years), 69 TB episodes occurred in schoolchildren and 4 TB episodes occurred in staff, yielding annual incidence rates of 524/100,000 (95% CI 414-663/100,000) person-years and 256/100,000 (95% CI 96-683/100,000) person-years, respectively. Of 1,412 schoolchildren diagnosed with TBI, 1,192 received TPT. Schoolchildren who received TPT had 79% lower risk of TB disease (adjusted hazard ratio [aHR] 0.21; 95% CI 0.07-0.69; p = 0.010) compared to non-recipients, the primary study outcome. Protection was greater in recent contacts (aHR 0.07; 95% CI 0.01-0.42; p = 0.004), the secondary study outcome. The prevalence of recent contacts was 28% (1,843/6,582). Two different TPT regimens were used (3HR and 4R), and both were apparently effective. No staff receiving TPT developed TB. Overall, between 2017 and 2019, TB disease incidence decreased by 87%, from 837/100,000 (95% CI 604-1,129/100,000) person-years to 110/100,000 (95% CI 36-255/100,000) person-years (p < 0.001), and TBI prevalence decreased by 42% from 19% (95% CI 18%-20%) to 11% (95% CI 10%-12%) (p < 0.001). A limitation of our study is that TB incidence could be influenced by secular trends during the study period.

conclusionsIn this study, following implementation of a school-wide TB screening and preventive treatment program, we observed a significant reduction in the burden of TB disease and TBI in children and adolescents. The benefit of TPT was particularly marked for recent TB contacts. This initiative may serve as a model for TB detection and prevention in children and adolescents in other communities affected by TB.

Indexed as

RefugeesAdolescentAdultAntitubercular AgentsChildFemaleHumansIncidenceIndiaMaleMass ScreeningMiddle AgedPrevalenceSchoolsTibetTuberculosisAntitubercular Agents

Identifiers

PMID33465063
PMCPMC7853467
OpenAlexW3124437482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.